专利号:US-12351573-B2 优先权日:2019-05-09 标 题:Compounds for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; CHENG KAI FAN 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
专利号:US-2023159450-A1 优先权日:2020-05-08 标 题 :Dimers for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; ALTITI AHMAD 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Dimers for use in synthesis of peptidomimetics are described. Uses of dimers as synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the dimers and uses of azapeptides and other peptidomimetics are also described.
专利号:EP-0443532-B1 优先权日:1990-02-20 标题:Temporary minimal protection synthesis of LH-RH analogs 发明人:NESTOR JOHN J JR; MCCLURE NATALIE L 权利人:SYNTEX INC 摘要:A solid phase synthesis of LH-RH analogs in which the amino acids serine and histidine, if present, are side chain protected during the synthesis with groups labile to selected alpha -amino or deprotecting agents.
专利号:US-12391691-B2 优先权日:2018-11-16 标题:Synthesis of key intermediate of KRAS G12C inhibitor compound 发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY 权利人:AMGEN INC 摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1 优先权日:2019-11-14 标题 :Synthesis of kras g12c inhibitor compound 发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN 权利人:AMGEN INC 摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-5212288-A 优先权日:1990-02-20 标 题:Temporary minimal protection synthesis of serine-containing polypeptides 发明人:NESTOR JR JOHN J; MCCLURE NATALIE L; ARZENO HUMBERTO 权利人:SYNTEX INC 摘要:In a process for the solid phase synthesis of a polypeptide containing at least one serine residue, the improvement comprising temporarily protecting the side chain of the serine residue with a protecting group which is removed immediately following the addition of the serine to the peptide chain.
1: Ludwig C, Desmoulins PO, Driancourt MA, Goericke-Pesch S, Hoffmann B. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant "Gonazon"; a preclinical trial. Theriogenology. 2009 Apr 15;71(7):1037-45. doi: 10.1016/j.theriogenology.2008.10.015. Epub 2009 Feb 23. 7: Heinig J, Coenen-Worch V, Cirkel U. Acute exacerbation of chronic maxillary sinusitis during therapy with nafarelin nasal spray. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):266-7. Polish. 11: Bergqvist A; SCANDET Group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecol Endocrinol. 2000 Dec;14(6):425-32.
合成参考文献
参考文献:10.1210/jc.81.10.3802|10.1210/jcem.81.10.8855841 摘要:Rosenthal IM, Refetoff S, Rich B, Barnes RB, Sunthornthepvarakul T, Parma J, Rosenfield RL. Response to challenge with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor--a clinical research center study. The Journal of Clinical Endocrinology & Metabolism. 1996 Oct;81(10):3802–6. doi: 10.1210/jcem.81.10.8855841. 参考文献:10.1023/a:1016072205371 摘要:Rodríguez Bayón AM, Guy RH. Iontophoresis of nafarelin across human skin in vitro. Pharm Res. 1996 May;13(5):798–800. doi: 10.1023/a:1016072205371. 参考文献:10.3109/09513599609027984 摘要:Avrech OM, Goldman GA, Pinkas H, Amit S, Neri A, Zukerman Z, Ovadia J, Fisch B. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial. Gynecol Endocrinol. 1996 Jun;10(3):165–70. doi: 10.3109/09513599609027984. 参考文献:10.1515/jpem.1996.9.1.9 摘要:Kletter GB, Rolfes-Curl A, Goodpasture JC, Solish SB, Scott L, Henzl MR, Beitins IZ. Gonadotropin-releasing hormone agonist analog (nafarelin): a useful diagnostic agent for the distinction of constitutional growth delay from hypogonadotropic hypogonadism. J Pediatr Endocrinol Metab. 1996 Jan;9(1):9–19. doi: 10.1515/jpem.1996.9.1.9. 摘要:Palatyński A, Gruszczyńska J, Sobkiewicz S. [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis]. Ginekol Pol. 2001 May;72(5):284–9.